- Home
- UL vs ABBV Comparison
UL vs ABBV Comparison
Compare UL & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UL | ABBV |
|---|---|---|
| Founded | 1930 | 2012 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.0B | 400.9B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | UL | ABBV |
|---|---|---|
| Price | $65.17 | $221.96 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 20 |
| Target Price | N/A | ★ $239.16 |
| AVG Volume (30 Days) | 2.1M | ★ 5.9M |
| Earning Date | 07-31-2025 | 02-04-2026 |
| Dividend Yield | ★ 3.50% | 3.13% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.32 | 1.32 |
| Revenue | ★ $70,194,950,090.00 | $59,644,000,000.00 |
| Revenue This Year | N/A | $10.38 |
| Revenue Next Year | N/A | $9.52 |
| P/E Ratio | ★ $19.47 | $167.16 |
| Revenue Growth | N/A | ★ 7.40 |
| 52 Week Low | $61.11 | $164.39 |
| 52 Week High | $73.87 | $244.81 |
Technical Indicators
Market Signals| Indicator | UL | ABBV |
|---|---|---|
| Relative Strength Index (RSI) | 57.32 | 45.59 |
| Support Level | $61.78 | $215.85 |
| Resistance Level | $64.56 | $237.04 |
| Average True Range (ATR) | 0.64 | 5.12 |
| MACD | -0.17 | -0.77 |
| Stochastic Oscillator | 76.83 | 29.83 |
Price Performance
Historical ComparisonAbout UL Unilever PLC
Unilever is a diversified beauty, wellbeing, and personal care (44% of 2024 sales by value), homecare (20%), and packaged food (36%) company. Its brands include Dove personal-care products, Knorr soups and sauces, Hellmann's mayonnaise, Axe and Rexona deodorants, and TRESemmé haircare. The firm has been acquisitive in recent years; notable purchases include Paula's Choice, Liquid I.V., Horlicks, and Wild deodorants. The company derives 58% of its sales from emerging markets and 42% from developed markets. The US is its largest market, accounting for around 20% of sales, followed by India, which accounts for 11% of sales.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.